International Biotechnology (LON:IBT – Get Free Report) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 965.99 and traded as high as GBX 1,145. International Biotechnology shares last traded at GBX 1,115, with a volume of 167,929 shares traded.
International Biotechnology Stock Performance
The company has a debt-to-equity ratio of 9.43, a quick ratio of 0.32 and a current ratio of 0.11. The firm’s 50 day simple moving average is GBX 1,022.34 and its 200 day simple moving average is GBX 965.99. The firm has a market capitalization of £354.88 million, a price-to-earnings ratio of 4.61 and a beta of 0.32.
International Biotechnology (LON:IBT – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported GBX (4.83) EPS for the quarter. The business had revenue of GBX 24 million during the quarter. International Biotechnology had a net margin of 82.27% and a return on equity of 27.35%. Sell-side analysts forecast that International Biotechnology will post 0.9435943 earnings per share for the current fiscal year.
About International Biotechnology
The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.
The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services.
Recommended Stories
- Five stocks we like better than International Biotechnology
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for International Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
